Coherus is a leading global biosimilar company. We are committed to improving patient lives by expanding access to life-changing biologic medicines.
Location: United States, California, Camarillo
Employees: 201-500
Total raised: $105M
Founded date: 2010
Investors 5
| Date | Name | Website |
| - | F-Prime Ca... | fprimecapi... |
| - | RA Capital... | racap.com |
| - | Sofinnova ... | sofinnova.... |
| - | Kohlberg K... | kkr.com |
| - | Eight Road... | eightroads... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 02.02.2021 | - | $50M | - |
| 19.05.2014 | Series C | $55M | - |
Mentions in press and media 15
| Date | Title | Description |
| 01.09.2026 | Senticell Raises $7M in Seed Funding | Senticell, a Philadelphia, PA-based biotechnology company developing a new class of liquid biopsy built on red blood cell (RBC)-bound nucleic acids, raised $7M in Seed funding. Backers included The Venture City, Capital Factory, Scalpel Ven... |
| 15.07.2024 | HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer | ROCKVILLE, Md. and SEOUL, South Korea, July 15, 2024 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS) announced today the appointment of Christopher W. Slavinsky as Chief Business Development and Legal Officer. HanAll Biopharma Appoints Ch... |
| 27.06.2024 | Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction | REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend Industrial Co. Ltd. (HKF) for up-front all-cash... |
| 13.03.2024 | Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update | – Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 – – CIMERLI® net sales of $52.4 million in the fourth quarter and... |
| 13.03.2024 | Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update | - |
| 05.03.2024 | Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 | - |
| 22.01.2024 | Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal | - |
| 17.11.2021 | Deloitte Fast 500: Medical device company takes the top spot but software continues to dominate the top 10 | For the 26th straight year, software companies continued to dominate the Deloitte Technology Fast 500, but biotech and medical device companies also captured top spots. Axonics (Nasdaq: AXNX), a medical technology company, topped the 2021 l... |
| 02.02.2021 | Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences | - |
| 29.12.2019 | FDA to decide on Spectrum Pharmaceuticals’ neutropenia drug by Oct. 2020 | In a note to investors, B. Riley FBR analyst Mayank Mamtani wrote that the drug would see a likely approval and launch around the fourth quarter of next year, with an entry into the G-CSF market – valued at $3 billion or more – in 2021. The... |
Show more